Abstract-NEP (neprilysin) is a widely expressed membrane-bound metalloprotease, which binds and cleaves a variety of peptides including vasodilators, natriuretics, and diuretics. Higher levels of NEP result in hypertension-a cardinal feature of the placental disease preeclampsia. Syncytiotrophoblast-derived extracellular vesicles (EVs), comprising microvesicles and exosomes, are released into the peripheral circulation in pregnancy and are postulated as a key mechanism coupling placental dysfunction and maternal phenotype in preeclampsia. We aimed to determine whether higher levels of active NEP are found in syncytiotrophoblast-derived EVs in preeclampsia compared with normal pregnancy. Using immunostaining and Western blotting, we first demonstrated that NEP levels are greater not only in preeclampsia placental tissue but also in syncytiotrophoblast-derived microvesicles and exosomes isolated from preeclampsia placentas (P<0.05, n=5). We confirmed placental origin using antibody-coated magnetic beads to isolate NEP-bound vesicles, finding that they stain for placental alkaline phosphatase. NEP on syncytiotrophoblastderived EVs is active and inhibited by thiorphan (P<0.01, n=3; specific inhibitor). Syncytiotrophoblast-derived microvesicles, isolated from peripheral plasma, demonstrated higher NEP expression in preeclampsia using flow cytometry (P<0.05, n=8). We isolated plasma exosomes using size-exclusion chromatography and showed greater NEP activity in preeclampsia (P<0.05, n=8). These findings show that the placenta releases active NEP into the maternal circulation on syncytiotrophoblast-derived EVs, at significantly greater levels in preeclampsia. NEP has pathological roles in hypertension, heart failure, and amyloid deposition, all of which are features of preeclampsia. Circulating syncytiotrophoblast-derived EV-bound NEP thus may contribute to the pathogenesis of this disease. (Hypertension.
P reeclampsia is a pregnancy-specific syndrome characterized by new-onset hypertension and proteinuria in the second half of pregnancy but often associated with more widespread organ dysfunction. 1, 2 Worldwide preeclampsia occurs in 2% to 8% of pregnancies, and it is one of the major global causes of maternal and fetal mortality. 3 A pathological process of systemic vascular inflammation and endothelial activation in preeclampsia can affect multiple organs, including the peripheral vasculature (hypertension), liver (hepatocellular necrosis), kidneys (acute glomerular dysfunction or, more rarely, tubular or renal cortical necrosis), central nervous system (seizures and intracerebral hemorrhage), and the heart (left ventricular hypertrophy with diastolic dysfunction). [4] [5] [6] [7] The proximate cause of preeclampsia is the placenta since the disease is pregnancy specific, can occur in molar pregnancies or trophoblast tumors (where no fetal tissue is present), and resolves only after delivery of the placenta. 8 Poor placentation in early pregnancy, specifically with inadequate spiral artery remodeling, appears to predate the clinical syndrome of preeclampsia. 9 The mechanism by which a chronically hypoxic placenta causes such diffuse multiorgan dysfunction in the mother remains elusive.
The syncytiotrophoblast is the layer of placenta in direct contact with maternal blood, with a total surface area of ≤10 m 2 . 10 Up to 3 g per day of extracellular vesicles (EVs) are released from syncytiotrophoblast into the maternal circulation at term. Significantly higher levels of syncytiotrophoblast-derived extracellular vesicles (STBEV) are found in the peripheral blood of women with preeclampsia than those with normal pregnancies (NP). 11 It is consequently postulated that STBEV could be the missing link between the placental dysfunction and later clinical associated maternal syndrome in preeclampsia. 12 To explore this hypothesis, we performed a proteomic analysis of STBEV released during dual-lobe placental perfusion from 8 women with preeclampsia and 7 women with NP (unpublished data). This showed that NEP (neprilysin) was upregulated in STBEV from women with preeclampsia.
NEP, also known as CD10 (neprilysin), CALLA (common acute lymphocytic leukemia antigen), or MME (membrane metalloendopeptidase), is a zinc metalloendopeptidase with a wide tissue distribution. It cleaves and inactivates a variety of bioactive peptides. 13 NEP inhibitors have recently attracted attention in cardiovascular medicine as a novel treatment for heart failure.
14 By inhibiting the degradation of endogenous vasoactive peptides, NEP inhibitors promote vasodilatation and prevent sodium retention and consequently counter pathological cardiac remodeling. 15 In previous studies, Li et al 16 reported greater expression of placental NEP in preeclampsia pregnancies, localized to the surface and cytoplasm of trophoblast cells. Buhimschi et al 17 found increased NEP in the urine of women with severe preeclampsia. No group has previously reported on NEP expression and activity in STBEV.
We hypothesized that NEP expression and activity are upregulated in STBEV from women with preeclampsia compared with NP and might contribute to the clinical syndrome of preeclampsia.
Methods
The raw data that support the findings of this study are available from the corresponding author on reasonable request.
Human Subjects
Approval for this project was granted by the Central Oxfordshire Research Ethics Committee (07/H0607/74 and 07/H0606/148). Women recruited for this study provided written informed consent; clinical characteristics are described in the Table. According to the criteria defined by the International Society for the Study of Hypertension in Pregnancy, de novo hypertension (blood pressure >140/90 mm Hg) and proteinuria (>300 mg/day) after gestational week 20 were used to diagnose preeclampsia. Women with NP had singleton pregnancies and no evidence of preeclampsia or previous hypertensive disorders.
Peripheral blood was taken from the left antecubital fossa and collected in 4.5 mL citrate tubes using a 21-gauge needle. Samples were centrifuged at 1500g for 15 minutes, and the platelet-poor plasma (PPP) was collected. Aliquots of 1 mL PPP were stored at −80°C in preparation for flow cytometry analysis and EV isolation. PPP samples collected from women with preeclampsia and NP were matched according to gestational age. Placentae were collected at the time of elective caesarean section (a different cohort of patients).
Immunohistochemistry
Paraffin-embedded placental tissue sections from NP and preeclampsia placentas were cut at 8 μm and attached onto slides. Tissues were stored at room temperature until use. Sections were heated at 62°C for 30 minutes, immersed in Histo-Clear (National Diagnostics, Atlanta) and rehydrated using ethanol. Antigens were retrieved using 10 mmol/L sodium citrate buffer, and endogenous peroxidase activity was blocked with 3% v/v hydrogen peroxide. The sections were treated with blocking agent 10% v/v fetal calf serum in PBS for 1 hour and incubated overnight at 4°C with mouse monoclonal antibodies: anti-NEP (1:25, ab951; Abcam, Cambridge, United Kingdom) and anti-IgG1 (1:25, 400153; BioLegend, CA). VECTASTAIN Elite ABC Kit (Vector Laboratories, Peterborough, United Kingdom) reagents were used to incubate sections at room temperature in biotinylated horse anti-mouse IgG secondary antibody for 1 hour and enhancer reagent for 30 minutes. Exposure to DAB Substrate Kit (Vector Laboratories) was used to detect specific antibody binding, and nuclei were stained with Shandon Harris Hematoxylin (Thermo Fisher Scientific, MA). Sections were dehydrated using ethanol, mounted with Depex (VWR, Philadelphia), and imaged using a Leica DM2500 optical microscope (Leica Microsystems, Wetzlar, Germany) with a Micropublisher 5.0 RTV camera system (QImaging, Surrey, Canada).
Isolation and Characterization of STBEV
Placental perfusate from a dual placental lobe perfusion system was centrifuged to pellet fractions containing STBMV (10 000g) and syncytiotrophoblast-derived exosomes (STBEX) (150 000g). The method has previously been described in detail by Dragovic et al. 18 A BD LSRII flow cytometer (BD Biosciences, CA) was used to phenotype STBMV, and the NanoSight NS500 system (Malvern Instruments, Malvern, United Kingdom) was used to measure the size and concentration of STBEX using nanoparticle tracking analysis. The protein concentration of isolated STBMV and STBEX was determined by the bicinchoninic acid protein assay, and STBEVs were stored at −80°C until further use.
Western Blotting
Western blotting was performed using placental lysate (18 µg) and STBEV (6 µg) from NP and preeclampsia placentas. STBMV and STBEX were treated with HEPES lysis buffer 1:1 (50 mmol/L HEPES, pH 7.5; 2% SDS; 10% glycerol). Western blots were incubated overnight at 4°C with mouse monoclonal anti-NEP antibody (1:1000, ab951; Abcam) and mouse monoclonal anti-PLAP (placental alkaline phosphatase) antibody (1:1000; NDOG2, in-house antibody). After incubation with HRP-conjugated anti-mouse IgG antibody (1:4000) for 1 hour at room temperature, Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) was used for chemiluminescence detection of antigens on x-ray film. Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories, CA) was used to stain total protein, and bands were normalized to this using ImageJ, version 1.51 (public domain).
Immunoprecipitation
Dynabeads Sheep Anti-Mouse IgG (50 µL; Life Technologies, CA) were incubated overnight at 4°C with either anti-NEP antibody (6 µg/mL, MA1-19086; Thermo Fisher Scientific), anti-PLAP antibody (6 µg/mL; NDOG2, in-house antibody), or anti-IgG1 isotype control antibody (6 µg/mL, 400153; BioLegend). STBEV from NP placentas were incubated for 10 minutes at 4°C with 10× FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany). Antibodycoated Dynabeads were then incubated overnight at 4°C with 25 µg of blocked STBMV or STBEX in PBS. Unbound sample was washed using PBS and STBEV separated from the Dynabeads by reducing agent, 1× Laemmli Sample Buffer (Bio-Rad Laboratories, CA) and centrifugation at 13 000 RPM. Western blotting was performed on isolated STBEV, and blots were probed using anti-NEP antibody (1:1000, ab951; Abcam) and anti-PLAP antibody (1:1000, NDOG2, in-house antibody).
NEP Activity of STBEV
NEP activity in STBEV derived from NP placentas was determined using the SensoLyte 520 Neprilysin Activity Assay Kit (AnaSpec, CA 
Flow Cytometry Analysis
PPP samples from women with preeclampsia and NP were matched according to gestational age. Flow cytometry was used to specifically interrogate STBMV for NEP (the protocol used has been previously described 20, 21 ). We have previously described in detail the measures to remove contaminants, the use of PPP for labeling with target antibody, and data acquisition using appropriate control gates. Alterations to our previously published method were as follows: (1) samples were stained using PLAP-preeclampsia (0.05 µg/mL; NDOG2, in-house antibody) and NEP-APC antibody 
Plasma EV Isolation and Activity Assay
PPP samples from women with preeclampsia and NP were analyzed together with nonpregnant samples (included as an additional control). Samples were centrifuged at 13 000g for 2 minutes to make platelet-free plasma, then 300 µL of each sample was processed using Izon qEVsingle columns (Izon Science, Christchurch, New Zealand). Columns were used according to manufacturer's guidelines and enabled EV to be purified from platelet-free plasma using size exclusion chromatography. Isolated exosomes in fractions 6 to 8 (600 µL) were collected in PBS buffer and concentrated using Amicon Ultra-4 Centrifugal Filter Units (Merck Millipore, MA). A final volume of 110 µL was then measured for NEP activity and analyzed using nanoparticle tracking analysis. Following the same protocol as the STBEV activity assay, duplicate readings were recorded for NEP activity in 50 µL of isolated EV. 
Statistical Analysis
Data were analyzed using GraphPad Prism 7 (GraphPad Software, CA). Either paired Student t test or unpaired Welch t test was applied, assuming gaussian distribution, and values were expressed as mean±SEM.
Results

Upregulated NEP Expression in Preeclampsia Placenta and STBEV
Strong NEP staining was observed on preeclampsia placental tissue ( Figure 1A ), compared with weak NEP staining on NP placental tissue ( Figure 1B ) and absent staining with control IgG1 antibody on preeclampsia placental tissue ( Figure 1C ). NEP expression was consistent, localized on the syncytiotrophoblast, and confirmed previous results by Li et al. 16 Findings were corroborated by Western blot analysis of preeclampsia and NP placental lysate; an 11-fold increase in NEP expression was detected (n=3; P<0.05; Figure 1D ). Increased levels of NEP were also present in preeclampsia STBMV (2.3-fold; n=5; P<0.05; Figure 1E ) and preeclampsia STBEX (4.3-fold; n=5; P<0.05; Figure 1F ) derived by placental perfusion. An enrichment of NEP expression in STBEV relative to placental lysate was also observed, and all samples were positive for PLAP-an syncytiotrophoblast marker.
Active NEP is Coexpressed With PLAP in STBEV
STBEVs were isolated using either anti-PLAP or anti-NEP antibody on magnetic Dynabeads (Figure 2A ). Western blot analysis identified that STBEVs precipitated using anti-NEP antibody were positive for PLAP, and conversely, STBEVs precipitated using anti-PLAP antibody were positive for NEP ( Figure 2B ). This confirmed that NEP was coexpressed with PLAP on the same population of STBEV (n=3).
NEP activity was quantified by measuring rate of accumulation of a substrate (5-FAM); thiorphan was used as a specific NEP inhibitor. A dose response of thiorphan on NEP activity revealed an optimal concentration of 0.1 umol/L (data not shown). Increasing the protein concentration of STBMV and STBEX increased NEP activity, which could be blocked with almost 100% efficacy by thiorphan ( Figure 3A and 3B) . 
NEP-Positive STBMV Events Are Significantly Elevated in Preeclampsia Plasma
PPP from women with preeclampsia and gestational agematched NP was analyzed using flow cytometry to determine PLAP+ and NEP+ events (a gating strategy previously published by us was used to exclude EV originating from non-syncytiotrophoblast cell types 20 ). We first confirmed the previously well-described 23 increase in STBMV events positive for PLAP in plasma derived from preeclampsia (4188±11157) compared with NP (1398±641; Figure 4A ). We found a significant increase in PLAP and NEP double-positive events per mL in STBMV from preeclampsia (2730±731) compared with NP plasma (805±350; P<0.05; Figure 4B ).
NEP Activity Is Higher in EV Isolated From Preeclampsia Plasma
EVs were isolated from preeclampsia, and gestational age matched NP peripheral venous plasma (n=8) using size exclusion chromatography. NEP activity was higher in EV from preeclampsia plasma than NP (P<0.05; Figure 5A ). EV purified from platelet-free plasma samples of healthy, nonpregnant controls (n=3) had significantly less NEP activity than EV NP (P<0.05; Figure 5B ) consistent with the latter being of placental origin.
Discussion
This study is the first to investigate peripherally circulating NEP expression and activity in preeclampsia. It demonstrates that NEP is expressed in the placenta (at the syncytiotrophoblast) and in the peripheral circulation on STBEV, where it is coexpressed with PLAP. It reports that NEP expression is upregulated in preeclampsia STBEV isolated by placental perfusion (both in STBMV and STBEX) compared with normal placentae. Moreover, it shows that circulating levels of STBMV and circulating exosomes have more NEP activity in preeclampsia. This NEP is biologically active and can be inhibited by a specific inhibitor, thiorphan. These findings are novel. Our findings corroborate an existing published report of increased NEP expression in preeclampsia syncytiotrophoblast. 16 NEP has many potential signaling functions. The most relevant to preeclampsia is enhanced degradation of multiple types of vasopeptides (including ANP [atrial natriuretic peptide], BNP [brain natriuretic peptide], oxytocin, endothelin, and bradykinin), 13, 15 whose roles are normally to maintain vasodilatation, natriuresis, and diuresis. As such, NEP might contribute to the defining hallmark of preeclampsia, namely hypertension, although its actions are difficult to predict given their pleotropicity.
NEP inhibitors have recently been successfully trialled in combination with angiotensin inhibitors in the treatment of heart failure in nonpregnant individuals. 15 A double-blind randomized trial of a combined NEP-angiotensin inhibitor compared with angiotensin inhibitor alone was stopped early because of substantial reduction in all-cause mortality, despite the trial being powered only for cardiovascular mortality. 14 Authors hypothesized that inhibiting the broader effects of NEP in heart failure (affecting multiple vasoactive peptides) underlies its likely effect on neurohormonal systems, sodium retention, and myocardial remodeling. During NP, women also undergo significant cardiac remodeling. 24 In preeclampsia, the cardiovascular burden associated with hypertension and increased peripheral resistance imposes extra changes such that 50% of these women develop left ventricular diastolic dysfunction and a further 20% biventricular systolic dysfunction and severe left ventricular hypertrophy. 7 Some researchers believe that this cardiac dysfunction induces changes in the placenta resulting in the preeclampsia syndrome. 25 Our data convincingly show that NEP signaling via the placenta is upregulated in preeclampsia; we hypothesize that increased NEP might contribute to the cardiac remodeling seen in preeclampsia, as has been suggested by NEP inhibition outside pregnancy. 15 Further studies are required. Strengths of this study include the use of multiple experimental approaches to corroborate findings. STBEVs were isolated by placental perfusion and from peripheral plasma, using differential ultracentrifugation, immunoprecipitation, size-exclusion chromatography, and flow cytometry. STBEVs were identified at every stage using PLAP-a unique marker of trophoblast-derived material, and double-positivity for PLAP and NEP was shown bidirectionally. Moreover, biological activity of STBEV-bound NEP was confirmed in samples sourced in different ways, providing strong evidence that NEP could play a signaling role. Our study has some limitations. Our placental perfusion data show greater upregulation of NEP in preeclampsia on STBEX than STBMV. However, size limitations prevent STBEX from being analyzed by flow cytometry. Our size-exclusion chromatography data did not exclude nonplacental exosomes; thus, although all our data point toward STBEX being the source of circulating NEP, it is not technically possible to demonstrate this in peripheral plasma samples.
Future work should focus on the expression and role of NEP in NP, to determine whether NEP could form part of a diagnostic or prognostic test in preeclampsia. NEP also represents a potentially exciting therapeutic target in preeclampsia, although more work is needed to determine the biological function of STBEV-bound NEP in preeclampsia on both vasoactive peptides and myocardial tissue. Notably, oxytocin is a recognized substrate of NEP 13 ; although no studies have evaluated oxytocin levels in preeclampsia compared with NP. Regulation of the NEP gene by histone deacetylation has been reported in the context of diabetes mellitus. 26 These authors reported an increase in cardiac NEP as a result of this. Interestingly, histone deacetylation is reported to play a role in preeclampsia by altering trophoblast cell migration. 27 It is possible that such histone deacetylation might regulate placental NEP, but further work is required to elucidate this.
Perspectives
We have demonstrated that enzymatically active NEP is released into the maternal circulation, bound to STBEV, and its expression is increased in preeclampsia. These findings raise the possibility that NEP is an important mediator between placental pathology and the maternal phenotype of preeclampsia. NEP is known to break down key vasoactive molecules such as ANP, BNP, endothelin, and bradykinin, all of which have been shown to play a role in the pathogenesis of preeclampsia. These molecules are also involved in cardiovascular dysfunction, which is also a feature of preeclampsia. Clinical trials have been published demonstrating the efficacy of NEP inhibitors in both the treatment of heart failure and also of hypertension. Our findings raise the possibility of using NEP inhibitors in the treatment of preeclampsia. Additionally, identification of NEP STBEV could provide diagnostic applications.
